Optimal Prognostication of Patients with Coronary Stenoses in the Pre- and Post-PCI setting: Comments on TARGET FFR and DEFINE-FLOW Trials Presented at TCT Connect 2020.
Coronary flow reserve
coronary physiology
fractional flow reserve
intermediate stenosis
microvascular dysfunction
post-percutaneous coronary intervention
prognosis
Journal
European cardiology
ISSN: 1758-3764
Titre abrégé: Eur Cardiol
Pays: England
ID NLM: 101574780
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
05
02
2021
accepted:
08
02
2021
entrez:
17
5
2021
pubmed:
18
5
2021
medline:
18
5
2021
Statut:
epublish
Résumé
The body of evidence for the use of coronary physiology assessments to guide percutaneous coronary intervention (PCI) has been growing continuously in recent decades. Two studies presented during TCT Connect 2020 added insights into the prognostic value of coronary physiology measurements in pre- and post-PCI settings. The first study, TARGET FFR, assessed whether a post-PCI fractional flow reserve (FFR)-guided incremental optimisation strategy (PIOS) was superior to angiography-guided PCI. The second study, DEFINE-FLOW, assessed the course of stenoses with fractional and coronary flow reserve (FFR+/CFR-) discordance when treated medically. This article summarises the main results from the TARGET FFR and the DEFINE-FLOW trials and puts them into the context of the existing literature.
Identifiants
pubmed: 33995587
doi: 10.15420/ecr.2021.04
pmc: PMC8117135
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e17Informations de copyright
Copyright © 2021, Radcliffe Cardiology.
Déclaration de conflit d'intérêts
Disclosure: The authors have no conflicts of interest to declare
Références
Circ Cardiovasc Interv. 2020 Sep;13(9):e009232
pubmed: 32895005
EuroIntervention. 2019 Aug 29;15(5):457-464
pubmed: 30561367
JACC Cardiovasc Interv. 2017 May 22;10(10):986-995
pubmed: 28456699
J Am Heart Assoc. 2020 Jul 7;9(13):e015559
pubmed: 32573324
Nat Rev Cardiol. 2020 Oct;17(10):629-640
pubmed: 32409779
Eur Heart J. 2019 Aug 1;40(29):2455-2462
pubmed: 30608528
JACC Cardiovasc Interv. 2018 Oct 22;11(20):2099-2109
pubmed: 30336814
Circ Cardiovasc Interv. 2017 Aug;10(8):
pubmed: 28790165
Am J Cardiol. 1974 Jan;33(1):87-94
pubmed: 4808557
Circ Cardiovasc Interv. 2014 Jun;7(3):301-11
pubmed: 24782198
Am Heart J. 2017 Jan;183:1-9
pubmed: 27979031
Circ Cardiovasc Interv. 2019 May;12(5):e007428
pubmed: 31018666
Circulation. 2002 Jun 25;105(25):2950-4
pubmed: 12081986
JACC Cardiovasc Interv. 2020 Jan 13;13(1):20-29
pubmed: 31918939
JACC Cardiovasc Interv. 2020 Jul 27;13(14):1639-1650
pubmed: 32703590
Am Heart J. 2020 Apr;222:139-146
pubmed: 32062172
Am Heart J. 2019 Jul;213:66-72
pubmed: 31128504
Clin Cardiol. 2020 May;43(5):414-422
pubmed: 32037592
N Engl J Med. 2020 Apr 9;382(15):1395-1407
pubmed: 32227755
N Engl J Med. 2009 Jan 15;360(3):213-24
pubmed: 19144937
Circ Cardiovasc Interv. 2015 Aug;8(8):e002443
pubmed: 26245891
JACC Cardiovasc Interv. 2020 Aug 24;13(16):1920-1933
pubmed: 32819481
Eur Heart J. 2020 Jan 14;41(3):407-477
pubmed: 31504439
Circulation. 2001 Jun 19;103(24):2928-34
pubmed: 11413082
Eur Heart J. 2019 Jan 7;40(2):180-186
pubmed: 30596995
N Engl J Med. 2018 Jul 19;379(3):250-259
pubmed: 29785878
Int J Cardiol. 2020 Mar 1;302:34-35
pubmed: 31889563
N Engl J Med. 2012 Sep 13;367(11):991-1001
pubmed: 22924638
Eur Heart J. 2015 Dec 14;36(47):3312-9a
pubmed: 26033981